MedTrace Logo

Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients

NCT01100177 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2013-03-11

No results posted yet for this study

Summary

Sunitinib seems to be a promising treatment for the objective of this proposal: to evaluate the clinical activity of Sunitinib as first line therapy in patients who have measurable disease and to evaluate the safety of Sunitinib with radiation therapy.

Conditions

Interventions

DRUG

Sunitinib

Sunitinib 37.5mg/m2/d

RADIATION

Radiation

Radiation therapy (60Gy) 2 Gy per day during 30 days

Sponsors & Collaborators

  • Grupo Español de Investigación en Neurooncología

    lead OTHER

Principal Investigators

  • Carmen Balaña, Coordiantor · Hospital Germans Trias i Pujol, Badalona, Spain

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2011-12-31
Completion
2012-01-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01100177 on ClinicalTrials.gov